These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 37372437)
21. The fecal microbiome and serum concentrations of indoxyl sulfate and p-cresol sulfate in cats with chronic kidney disease. Summers SC; Quimby JM; Isaiah A; Suchodolski JS; Lunghofer PJ; Gustafson DL J Vet Intern Med; 2019 Mar; 33(2):662-669. PubMed ID: 30561098 [TBL] [Abstract][Full Text] [Related]
22. Dietary strategies for gut-derived protein-bound uremic toxins and cardio-metabolic risk factors in chronic kidney disease: A focus on dietary fibers. Melekoglu E; Samur FG Crit Rev Food Sci Nutr; 2023; 63(19):3994-4008. PubMed ID: 34704501 [TBL] [Abstract][Full Text] [Related]
23. SLC22A11 Inserts the Uremic Toxins Indoxyl Sulfate and P-Cresol Sulfate into the Plasma Membrane. Tust M; Müller JP; Fischer D; Gründemann D Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894870 [TBL] [Abstract][Full Text] [Related]
24. Diet Quality and Protein-Bound Uraemic Toxins: Investigation of Novel Risk Factors and the Role of Microbiome in Chronic Kidney Disease. McFarlane C; Krishnasamy R; Stanton T; Savill E; Snelson M; Mihala G; Morrison M; Johnson DW; Campbell KL J Ren Nutr; 2022 Sep; 32(5):542-551. PubMed ID: 34776340 [TBL] [Abstract][Full Text] [Related]
25. Proton pump inhibitor-induced risk of chronic kidney disease is associated with increase of indoxyl sulfate synthesis via inhibition of CYP2E1 protein degradation. Lu S; Zhao J; Chen X; Xu S; Yang X; Zhang Y; Ma Z; Jiang H; Zhou H Chem Biol Interact; 2022 Dec; 368():110219. PubMed ID: 36243147 [TBL] [Abstract][Full Text] [Related]
26. An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients. Cosola C; Rocchetti MT; di Bari I; Acquaviva PM; Maranzano V; Corciulo S; Di Ciaula A; Di Palo DM; La Forgia FM; Fontana S; De Angelis M; Portincasa P; Gesualdo L Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34063068 [TBL] [Abstract][Full Text] [Related]
27. Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease. Black AP; Cardozo LF; Mafra D Ther Apher Dial; 2015 Oct; 19(5):436-40. PubMed ID: 25944654 [TBL] [Abstract][Full Text] [Related]
28. Indoxyl sulfate, not p-cresyl sulfate, is associated with cognitive impairment in early-stage chronic kidney disease. Yeh YC; Huang MF; Liang SS; Hwang SJ; Tsai JC; Liu TL; Wu PH; Yang YH; Kuo KC; Kuo MC; Chen CS Neurotoxicology; 2016 Mar; 53():148-152. PubMed ID: 26797588 [TBL] [Abstract][Full Text] [Related]
29. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. Lau WL; Savoj J; Nakata MB; Vaziri ND Clin Sci (Lond); 2018 Mar; 132(5):509-522. PubMed ID: 29523750 [TBL] [Abstract][Full Text] [Related]
30. Effects of prebiotic oligofructose-enriched inulin on gut-derived uremic toxins and disease progression in rats with adenine-induced chronic kidney disease. Melekoglu E; Cetinkaya MA; Kepekci-Tekkeli SE; Kul O; Samur G PLoS One; 2021; 16(10):e0258145. PubMed ID: 34614017 [TBL] [Abstract][Full Text] [Related]
31. Correlation between Serum Levels of Protein-Bound Uremic Toxins in Hemodialysis Patients Measured by LC/MS/MS. Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T Mass Spectrom (Tokyo); 2013; 2(Spec Iss):S0017. PubMed ID: 24349936 [TBL] [Abstract][Full Text] [Related]
32. Link between gut microbiota dysbiosis and chronic kidney disease. Noce A; Marchetti M; Marrone G; Di Renzo L; Di Lauro M; Di Daniele F; Albanese M; Di Daniele N; De Lorenzo A Eur Rev Med Pharmacol Sci; 2022 Mar; 26(6):2057-2074. PubMed ID: 35363356 [TBL] [Abstract][Full Text] [Related]
33. Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Poesen R; Viaene L; Verbeke K; Claes K; Bammens B; Sprangers B; Naesens M; Vanrenterghem Y; Kuypers D; Evenepoel P; Meijers B Clin J Am Soc Nephrol; 2013 Sep; 8(9):1508-14. PubMed ID: 23813557 [TBL] [Abstract][Full Text] [Related]
34. Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis. Wakamatsu T; Yamamoto S; Yoshida S; Narita I Toxins (Basel); 2024 May; 16(6):. PubMed ID: 38922148 [TBL] [Abstract][Full Text] [Related]
35. Distal Colon Motor Dysfunction in Mice with Chronic Kidney Disease: Putative Role of Uremic Toxins. Hoibian E; Florens N; Koppe L; Vidal H; Soulage CO Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29772737 [TBL] [Abstract][Full Text] [Related]
36. Association of Sarcopenia and Gut Microbiota Composition in Older Patients with Advanced Chronic Kidney Disease, Investigation of the Interactions with Uremic Toxins, Inflammation and Oxidative Stress. Margiotta E; Caldiroli L; Callegari ML; Miragoli F; Zanoni F; Armelloni S; Rizzo V; Messa P; Vettoretti S Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357944 [TBL] [Abstract][Full Text] [Related]
37. Syndecan-1 and Free Indoxyl Sulfate Levels Are Associated with miR-126 in Chronic Kidney Disease. Fourdinier O; Glorieux G; Brigant B; Diouf M; Pletinck A; Vanholder R; Choukroun G; Verbeke F; Massy ZA; Metzinger-Le Meuth V; Metzinger L; Group-EUTox OBOTEUTW Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638892 [TBL] [Abstract][Full Text] [Related]
38. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001 [TBL] [Abstract][Full Text] [Related]
39. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Ito S; Yoshida M Toxins (Basel); 2014 Feb; 6(2):665-78. PubMed ID: 24561478 [TBL] [Abstract][Full Text] [Related]
40. Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change. Liu Y; Li J; Yu J; Wang Y; Lu J; Shang EX; Zhu Z; Guo J; Duan J J Pharm Biomed Anal; 2018 Feb; 149():425-435. PubMed ID: 29169110 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]